Monoamine Theories of Depression: Historical Impact on Biomedical Research

Monoamine theories associate depression with reduced brain monoamine levels. These theories achieved broad popularity in the mid-1960s. The present article reviews the historical development of monoamine theories and their subsequent impact on biomedical research. Alleged divisions between West European and US researchers over competing versions of the theories are investigated using bibliometrics. Subsequently, the application of monoamine theories in the NIMH Collaborative Program on the Psychobiology of Depression is covered. The article argues that the impact of monoamine theories is best explained by the ability of researchers, governmental agencies, and pharmaceutical companies to invoke theories that advance various projects and agendas.

[1]  A. Agresti.  An introduction to categorical data analysis , 1997 .

[2]  F. Ayd.  Diagnosis and Drug Treatment of Psychiatric Disorders , 1969 .

[3]  P. Whybrow,et al.  Abnormalities of indoleamines in affective disorders. , 1972, Archives of general psychiatry.

[4]  G. Oxenkrug,et al.  Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. , 1969, Lancet.

[5]  S. Koslow,et al.  Biological component of the NIMH Clinical Research Branch Collaborative Program on the psychobiology of depression: II. Methodology and data analysis , 1980, Psychological Medicine.

[6]  D. Murphy,et al.  New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. , 1984, The Journal of clinical psychiatry.

[7]  M. Sandler,et al.  A CLINICAL AND BIOCHEMICAL STUDY OF A TRIAL OF IPRONIAZID IN THE TREATMENT OF DEPRESSION , 1959, Journal of neurology, neurosurgery, and psychiatry.

[8]  M. Tarsh.  The History of Psychiatry , 1967, Mental Health.

[9]  S. Koslow,et al.  CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis. , 1983, Archives of general psychiatry.

[10]  S. Schlozman,et al.  The Antidepressant Era , 1998 .

[11]  J. Maas.  Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. , 1975, Archives of general psychiatry.

[12]  J. Lacasse,et al.  Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature , 2005, PLoS medicine.

[13]  T. Baum,et al.  The pharmacology of iprindole, a new antidepressant , 1969, Psychopharmacologia.

[14]  M. Wilson,et al.  DSM-III and the transformation of American psychiatry: a history. , 1993, The American journal of psychiatry.

[15]  Henk F. Moed,et al.  Citation Analysis in Research Evaluation , 1899 .

[16]  Schildkraut Jj.  The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. , 1995 .

[17]  A. Coppen,et al.  Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. , 1963, Lancet.

[18]  R. Baldessarini.  Biogenic amines and behavior. , 1972, Annual review of medicine.

[19]  L. Whitby,et al.  Effect of Psychotropic Drugs on the Uptake of H3-Norepinephrine by Tissues , 1961, Science.

[20]  A. Carlsson,et al.  On the presence of 3-hydroxytyramine in brain. , 1958, Science.

[21]  T. Hökfelt,et al.  Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. , 1969, European journal of pharmacology.

[22]  Gregory Radick,et al.  The Century of the Gene , 2001, Heredity.

[23]  J. Moncrieff.  The creation of the concept of an antidepressant: an historical analysis. , 2008, Social science & medicine.

[24]  E. Robins,et al.  Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment , 1982, Psychological Medicine.

[25]  J. Mendels,et al.  Brain biogenic amine depletion and mood. , 1974, Archives of general psychiatry.

[26]  U. Ungerstedt,et al.  The effect of imipramine of central 5‐hydroxytryptamine neurons , 1968, The Journal of pharmacy and pharmacology.

[27]  S. Hyman,et al.  Initiation and adaptation: a paradigm for understanding psychotropic drug action. , 1996, The American journal of psychiatry.

[28]  D. Wong,et al.  A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. , 1974, Life sciences.

[29]  E. Nestler,et al.  A molecular and cellular theory of depression. , 1997, Archives of general psychiatry.

[30]  D. Charney,et al.  Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. , 1981, Archives of general psychiatry.

[31]  Modified amine hypothesis for the aetiology of affective illness. , 1972, Lancet.

[32]  J. B. Stanton,et al.  5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases. , 1966, Lancet.

[33]  Peter van Ham,et al.  Interview with the Author , 2001 .

[34]  M. Katz,et al.  The Psychology of depression : contemporary theory and research , 1974 .

[35]  U. Malm,et al.  ACID MONOAMINE METABOLITES OF CEREBROSPINAL FLUID IN MENTAL DEPRESSION AND MANIA , 1966, Journal of neurochemistry.

[36]  Sarah M. Uzelac,et al.  The Myth of Reserpine-Induced Depression: Role in the Historical Development of the Monoamine Hypothesis , 2003, Journal of the history of the neurosciences.

[37]  H. Buchtel,et al.  Neuronal plasticity: historical roots and evolution of meaning , 2008, Experimental Brain Research.

[38]  John M. Davis,et al.  Effect of iprindole on norepinephrine turnover and transport , 2004, Psychopharmacologia.

[39]  H. Weissbach,et al.  Effect of iproniazid on serotonin metabolism in vivo. , 1957, The Journal of pharmacology and experimental therapeutics.

[40]  R. Baldessarini.  The basis for amine hypotheses in affective disorders. A critical evaluation. , 1975, Archives of general psychiatry.

[41]  M. Åsberg,et al.  5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? , 1976, Archives of general psychiatry.

[42]  A. Coppen.  The Biochemistry of Affective Disorders , 1967, British Journal of Psychiatry.

[43]  E. Robins,et al.  Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study. , 1984, Archives of general psychiatry.

[44]  M. Shepherd,et al.  Reserpine in the treatment of anxious and depressed patients. , 1955, The Lancet.

[45]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[46]  D. Kupfer,et al.  Urinary MHPG and clinical response to amitriptyline in depressed patients. , 1980, The American journal of psychiatry.

[47]  J. Maas,et al.  Catecholamine metabolism, depressive illness, and drug response. , 1972, Archives of general psychiatry.

[48]  G. Klerman,et al.  CLINICAL PHARMACOLOGY OF IMIPRAMINE AND RELATED ANTIDEPRESSANT COMPOUNDS. , 1965, Pharmacological reviews.

[49]  N. Kline,et al.  Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. , 1954, Annals of the New York Academy of Sciences.

[50]  J. Mendels,et al.  Biological component of the NIMH Clinical Research Branch Collaborative Program on the psychobiology of depression: I. Background and theoretical considerations , 1980, Psychological Medicine.

[51]  J. M. Schneck.  A history of psychiatry , 1960 .

[52]  R. Post.  Molecular biology of behavior. Targets for therapeutics. , 1997, Archives of general psychiatry.

[53]  J. Schildkraut,et al.  The catecholamine hypothesis of affective disorders: a review of supporting evidence. , 1965, The American journal of psychiatry.

[54]  C. Holden.  Depression: the news isn't depressing. , 1991, Science.

[55]  S. Stahl.  Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action. , 1984, The Journal of clinical psychiatry.

[56]  W. Bunney,et al.  Norepinephrine in depressive reactions. A review. , 1965, Archives of general psychiatry.

[57]  E. Robins,et al.  Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. , 1984, The American journal of psychiatry.

[58]  J. Fouts,et al.  Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes , 1952, Experientia.

[59]  S. Agurell.  Biogenic amines and depression (Introduction to symposium) , 1981, Acta psychiatrica Scandinavica. Supplementum.

[60]  M. F. Sugrue,et al.  EFFECTS OF MIANSERIN, A NEW ANTIDEPRESSANT, ON THE in vitro AND in vivo UPTAKE OF MONOAMINES , 1977, British journal of pharmacology.

[61]  R. Hirschfeld,et al.  NIMH clinical research branch collaborative program on the psychobiology of depression. , 1979, Archives of general psychiatry.

[62]  E. Keller,et al.  Refiguring Life: Metaphors of Twentieth-Century Biology , 1995 .

[63]  M. Peet,et al.  Mianserin: a decade of scientific development. , 1978, British Journal of Clinical Pharmacology.

[64]  S. Kety,et al.  Biogenic Amines and Emotion , 1967, Science.

[65]  F. Goodwin,et al.  Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin. , 1979, Archives of general psychiatry.

[66]  A. Baumeister,et al.  The Serotonin Hypothesis of Schizophrenia: A Historical Case Study on the Heuristic Value of Theory in Clinical Neuroscience , 2004, Journal of the history of the neurosciences.

[67]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[68]  M. Åsberg,et al.  Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline , 1973, Clinical pharmacology and therapeutics.

[69]  T. Ban.  Prolegomenon to the clinical prerequisite: Psychopharmacology and the classification of mental disorders , 1987, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[70]  G L MADDOX,et al.  A critical evaluation , 2012 .

[71]  M. Åsberg,et al.  Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression , 1974, European Journal of Clinical Pharmacology.

[72]  T. Hökfelt,et al.  Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. , 1969, European journal of pharmacology.

[73]  J. Vetulani,et al.  Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain , 1975, Nature.

[74]  J. Glowinski,et al.  Inhibition of Uptake of Tritiated-noradrenaline in the Intact Rat Brain by Imipramine and Structurally Related Compounds , 1964, Nature.